Table 2.
Cases reported in literature of bicalutamide-induced liver injury.
| Author | Case* | Abnormal Laboratory* | Outcome | ||
|---|---|---|---|---|---|
| Initial | Later | ||||
| Dawson et al., 1997 [7] | A 60-year-old man with no prior history of liver disease received androgen blockade and localized radiation for prostate cancer (T3cN1M0 Gleason grade 7). CIOMS score not provided |
TB mg/dL | 19.47 | Nor | Hepatic failure improved. Prothrombin time, bilirubin and liver enzymes normalized within 2 months |
| GGT U/L | 121 | Nor | |||
| AST U/L | 1527 | Nor | |||
| ALT U/L | 2690 | Nor | |||
| APhos U/L | 181 | Nor | |||
| INR | 2.21 | Nor | |||
| Beza et al., 2008 [2] | A 61-year-old man with adenocarcinoma of prostate (T3bN0M0 Gleason grade 6) who received CAB with bicalutamide and LHRH agonist. CIOMS score not provided |
TB mg/dl | 11.57 | 49.88 | The clinical course deteriorated, and the patient died |
| DB mg/dl | 8.32 | 29.48 | |||
| AST U/L | 1335 | 216 | |||
| ALT U/L | 1923 | 158 | |||
| APhos U/L | 169 | NR | |||
| GGT U/L | 473 | NR | |||
| O’Bryant, et al., 2008 [8] | A 59-year-old man with metastatic prostate carcinoma (T4N1M1 Gleason grade 9) treated with bicalutamide as part of androgen deprivation therapy prior to chemotherapy. CIOMS score not provided |
AST U/L | 166 | 3206 | The patient died 8 days after bicalutamide therapy was begun secondary to multiorgan failure, as a result of fulminant hepatic failure |
| ALT U/L | 111 | 2050 | |||
| INR | NR | 3.4 | |||
*
CAB – combined androgen blockade; LHRH – luteinizing hormone receptor agonist; Initial – labs at admission; Subsequent – labs during the course of hospitalization; Nor – normalized but value not reported; NR – not reported; TB – total bilirubin; DT – direct bilirubin; AST – aspartate aminotransferase; ALT – alanine aminotransferase; APhos – alkaline phosphatase; GGT – gamma-glutamyl transpeptidase; INR – international normalized ratio; CIOMS – Council for International Organizations of Medical Sciences.